Bispecific antibodies and agents to enhance stem cell homing
First Claim
Patent Images
1. A composition, comprising:
- a bispecific antibody which binds CD34 on a mammalian stem cell and which binds an antigen on a mammalian endothelial cell, wherein the antigen is VAP-1, P-selectin, E-selectin, ICAM, VCAM or VLA; and
an amount of TNF-α
, IFNγ
, IL-1, or IL-4 selected to enhance expression of the antigen in mammalian endothelial cells relative to corresponding cells in the absence of the TNF-α
, IFNγ
, IL-1, or IL-4.
1 Assignment
0 Petitions
Accused Products
Abstract
A composition having a bispecific antibody which binds a stem cell specific antigen and a tissue, differentiated cell or condition associated antigen and an agent that enhances expression of the tissue, differentiated cell or condition associated antigen, is provided. Also provided are methods of using the bispecific antibodies and/or agents to enhance cell therapy.
77 Citations
19 Claims
-
1. A composition, comprising:
-
a bispecific antibody which binds CD34 on a mammalian stem cell and which binds an antigen on a mammalian endothelial cell, wherein the antigen is VAP-1, P-selectin, E-selectin, ICAM, VCAM or VLA; and an amount of TNF-α
, IFNγ
, IL-1, or IL-4 selected to enhance expression of the antigen in mammalian endothelial cells relative to corresponding cells in the absence of the TNF-α
, IFNγ
, IL-1, or IL-4. - View Dependent Claims (2, 3, 5, 6)
-
-
4. A composition, comprising:
-
a bispecific antibody which binds a stem cell specific antigen on a mammalian stem cell selected from CD34, CD133, ABCG2, Sca-1, Stro-1, Nestin, PSA-NCAm, p75 neurotrophin, c-kit, or CD30, and which binds VAP-1; and an amount of TNF-α
, IFNγ
, IL-1, or IL-4 selected to enhance expression of VAP-1 in mammalian endothelial cells relative to corresponding cells in the absence of the TNF-α
, IFNγ
, IL-1, or IL-4.
-
-
7. A method of enhancing localization and retention of stem cells, comprising:
delivering to a mammal in need of cell therapy an effective amount of bispecific antibodies which bind CD34 and which bind VAP-1, P-selectin, E-selectin, ICAM, VCAM or VLA, an amount of TNF-α
, IFNγ
, IL-1, or IL-4 that enhances expression of VAP-1, P-selectin, E-selectin, ICAM, VCAM or VLA in mammalian endothelial cells, and donor mammalian stem cells having CD34.- View Dependent Claims (8, 9, 10, 11, 12, 13, 14, 15, 16)
-
17. A method for targeting stem cells to a site of injury or inflammation, comprising:
- delivering to a mammal having a site of injury or inflammation an effective amount of bispecific antibodies which bind CD34 on a mammalian stem cell and which bind VAP-1, P-selectin, E-selectin, ICAM, VCAM or VLA on mammalian endothelial cells, an amount of TNF-α
, IFNγ
, IL-1, or IL-4 that enhances expression of VAP-1, P-selectin, E-selectin, ICAM, VCAM or VLA in mammalian endothelial cells, and donor mammalian stem cells having CD34, wherein the TNF-α
, IFNγ
, IL-1, or IL-4 is locally delivered to the site of injury or inflammation. - View Dependent Claims (18, 19)
- delivering to a mammal having a site of injury or inflammation an effective amount of bispecific antibodies which bind CD34 on a mammalian stem cell and which bind VAP-1, P-selectin, E-selectin, ICAM, VCAM or VLA on mammalian endothelial cells, an amount of TNF-α
Specification